Myditin (Pridinol Mesilate)

Pridinol mesilate, the active ingredient in Myditin, is a centrally acting muscle relaxant presented as an oral tablet for oral use. It reduces skeletal muscle tone and alleviates muscle spasm, providing relief in adults with acute musculoskeletal pain and other skeletal muscle disorders.

GNH USA supplies Myditin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable logistics for global healthcare providers. Our distribution network adheres to stringent temperature and humidity controls to maintain product integrity during transit.

Myditin (pridinol mesilate) acts on central anticholinergic pathways to relieve muscle‑related conditions.

- Muscle spasm: diminishes involuntary skeletal muscle contractions, reducing associated discomfort and functional limitation. - Musculoskeletal pain: eases pain arising from acute strain or injury of skeletal muscles, supporting better movement. - Skeletal muscle disorders: lowers excessive muscle tone, facilitating improved range of motion in various muscle disorders.

Pridinol mesilate may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dry mouth: reduced salivary secretion causing oral dryness. - Drowsiness: mild sedation affecting alertness. - Dizziness: sensation of lightheadedness or imbalance. - Nausea: mild gastrointestinal upset. - Constipation: decreased bowel motility. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, or swelling indicating hypersensitivity. - Severe skin rash: Stevens‑Johnson‑type reactions requiring immediate medical attention. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Cardiac arrhythmia: irregular heart rhythm potentially serious. - Seizures: rare occurrence of convulsive episodes.

When prescribing Myditin, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown excretion; weigh benefits against potential risks. - Renal impairment: use with caution; monitor renal function. - Elderly patients: increased sensitivity to CNS effects; start at low dose. - Concomitant anticholinergic drugs: may enhance anticholinergic burden. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Pridinol mesilate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other central anticholinergics: additive anticholinergic effects may cause severe dryness or confusion. - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Alcohol: potentiates CNS depression and sedation.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, opioids): may increase sedation and respiratory depression. - Antihistamines: can enhance anticholinergic side effects. - Antidepressants (tricyclics): may augment anticholinergic load.